Difference between revisions of "International Patient Summary (IPS)"
Line 85: | Line 85: | ||
''This is an incomplete list; for a wider report please refer to the IPS project in ART DECOR'' | ''This is an incomplete list; for a wider report please refer to the IPS project in ART DECOR'' | ||
+ | === Under Discussion=== | ||
+ | |||
+ | # [[IPS_NoInfos_section|Identification of codes for no data and known absent cases]] | ||
+ | # [[IPS_problemObservation|Pattern for problem observations (usage of "ASSERTION")]] | ||
# Sections to be included in the Patient Summary | # Sections to be included in the Patient Summary | ||
− | |||
# Value Sets | # Value Sets | ||
## Active Substances (medications; allergies) | ## Active Substances (medications; allergies) | ||
## Allergy Agents - substances (allergies) | ## Allergy Agents - substances (allergies) | ||
+ | |||
+ | |||
+ | |||
+ | === Solution agreed === | ||
+ | |||
+ | # [[IPS_NoInfos_section|How to express no data about medications, problems, allergies, ....]] | ||
+ | # Value Sets | ||
## (Manifestation of) Adverse Reaction | ## (Manifestation of) Adverse Reaction |
Revision as of 09:29, 28 February 2017
Contents
Scope
The International Patient Summary is a "Minimal and non-exhaustive Patient Summary, specialty-agnostic, condition-independent, but readily usable by all clinicians for the unscheduled (cross-border) care of a patient."
The goal of this project is to build an international document and associated templates based on HL7 CDA R2 (or a future CDA release) and potentially the FHIR standards, with value sets to support data elements within those templates.
These templates/profiles aim to:
- Serve for both cross-jurisdictional (through adaptation/extension for multi-language and realm scenarios, including translation) and national (through localization) patient summaries.
- Support emergency care and unplanned care in any country (home and foreign), regardless of language
- Define value sets based on international vocabularies that are usable and understandable in any country
Please refer to the PSS [1] for more details.
Meetings
Schedule
- Regular weekly calls on Wednesday 17-18.30 CET // 11-12.30 ET
- Additional monthly call (first Monday of each month) 22-23.30 CET // 16-17.30 EST // 8-9.30 (+ 1) AEDT )
Gotomeeting details
https://global.gotomeeting.com/join/399580637
Dial in using your phone.
Access Code: 399-580-637
United States: +1 (224) 501-3316 Australia: +61 2 9091 7603 Austria: +43 7 2088 0716 Belgium: +32 28 08 4372 Canada: +1 (647) 497-9372 Denmark: +45 69 91 84 58 Finland: +358 972 52 2971 France: +33 170 950 590 Germany: +49 692 5736 7206 Ireland: +353 19 030 053 Italy: +39 0 699 26 68 65 Netherlands: +31 208 080 759 New Zealand: +64 9 282 9510 Norway: +47 21 04 30 59 Spain: +34 931 76 1534 Sweden: +46 852 500 691 Switzerland: +41 435 0026 89 United Kingdom: +44 20 3713 5011
Minutes
- 20161228 - 17-18.30 CET // 11-12.30 EST (https://www.gotomeeting.com/join/399580637)
- 20161221 - 17-18.30 CET // 11-12.30 EST
- 20161214 - 17-18.30 CET // 11-12.30 EST
- 20161205 - 22-23.30 CET // 16-17.30 EST // 8-9.30 (+ 1) AEDT (https://www.gotomeeting.com/join/267067629)
- 20161130 (17-18.15 CET // 11-12.15 EST // 3-4.15 (+ 1) AEDT)
- 20161125 (19-20 CET // 13-14 EST // 5-6 (+ 1) AEDT)
- Brief report on the Oslo's meeting; intial discussion about the allergy and intollerance section presentation and notes taken during the call
- 20161114
- Preparation of the CEN/HL7 IPS meeting in Oslo (Nov 19th 2016) presentation and notes taken during the call
- 20161107
- 20161103
- 20161027
- 20161020
- 20161006
- Initial discussion about the medication summary section: presentation and notes taken during the call
Resources
- CHAT (https://chat.hausamconsulting.com/#narrow/stream/IPS)
- gforge repository (svn/strucdoc/trunk/IPS) [2]
- IPS CDA Templates repository (ART DECOR) [3]
- IPS dataset (ART DECOR) [4]
- Issues tracker (ART DECOR) [5]
- IPS Mailing List [6]
Hot Topics & Known Issues
This is an incomplete list; for a wider report please refer to the IPS project in ART DECOR
Under Discussion
- Identification of codes for no data and known absent cases
- Pattern for problem observations (usage of "ASSERTION")
- Sections to be included in the Patient Summary
- Value Sets
- Active Substances (medications; allergies)
- Allergy Agents - substances (allergies)
Solution agreed
- How to express no data about medications, problems, allergies, ....
- Value Sets
- (Manifestation of) Adverse Reaction